Anticoagulation for Mechanical Heart Valves
Will Oral Factor Xa Inhibitors Be Effective?

Noel C. Chan, Jeffrey I. Weitz, John W. Eikelboom

The global burden of valvular heart disease, which currently affects more than 100 million people, is growing with the aging population. Severe valvular heart disease is associated with major morbidity and mortality and often necessitates surgical valve replacement with a mechanical or a tissue valve. If the risk of surgery is prohibitive, transcatheter valve replacement is another option.

Although mechanical heart valves (MHV) are more durable than tissue valves, they are more thrombogenic. Consequently, patients with MHV require long-term anticoagulation with vitamin K antagonists, such as warfarin. Although effective, warfarin has well-known limitations, including multiple drug and food interactions, and the challenges of coagulation monitoring and maintaining the international normalized ratio within the therapeutic range. Indeed, variability in the international normalized ratio is a major independent predictor of reduced survival in patients with MHV. Consequently, there is a need for effective anticoagulants for MHV patients with better pharmacological profiles than warfarin.

Direct oral anticoagulants have replaced warfarin for many indications. These agents include dabigatran, which inhibits thrombin, and rivaroxaban, apixaban and edoxaban, which inhibit factor Xa. Despite the proven efficacy and safety of direct oral anticoagulants in the prevention of stroke in patients with atrial fibrillation, and in the prevention and treatment of venous thromboembolism, the unfavorable results of the RE-ALIGN (Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etxetilate in Patients after Heart Valve Replacement) trial prompted the FDA to issue black-box warnings against the use of direct oral anticoagulants in patients with MHV. In the RE-ALIGN trial, dabigatran etexilate was titrated up to a maximum dose of 300 mg twice daily (BID) to achieve a trough level above 50 ng/mL. Despite this targeted dosing, dabigatran was associated with a trend for an excess of ischemic strokes and a significant reduction in survival in patients with MHV. Consequently, there is a need for effective anticoagulants for MHV patients with better pharmacological profiles than warfarin.

Oral factor Xa inhibitors, such as apixaban, may be better than dabigatran for suppressing clotting on MHV. Therefore, it is possible that by inhibiting upstream factor Xa triggers the generation of 1000 molecules of thrombin. Thus, one molecule of factor Xa is an appropriate target for attenuating clotting on MHV.9

Does this mean that apixaban can be safely used instead of warfarin in humans with MHV? Although promising, the findings need to be interpreted with caution. First, the sample size (n=16) was small, so that efficacy comparisons with warfarin are underpowered. Second, the oral apixaban regimen administered in this study is a higher dose than that used in humans. Although the intravenous infusion regimen more closely mimicked apixaban dosing in humans, thrombus weight measurements were confounded by earlier assessment at day 14 instead of day 30. Finally, although the pig heterotopic aortic valve model is often used to test the efficacy of anticoagulants, it is uncertain whether the results from this model can be translated to humans. For instance, dabigatran was more effective than enoxaparin for preventing valve thrombosis in this model, but failed in humans in the RE-ALIGN study.

The RE-ALIGN trial results have improved our understanding of the mechanism of clotting on MHV. There is with these higher doses, dabigatran was less effective than warfarin at preventing clotting on MHV.

Why did dabigatran fail for this indication when it was successful in others? The failure likely reflects the fact that unlike the situation in atrial fibrillation and venous thromboembolism where thrombosis is initiated by tissue factor, clotting on MHV is triggered via activation of the contact system, resulting in the local generation of thrombin in concentrations that overwhelm those of dabigatran.7 One molecule of factor Xa triggers the generation of 1000 molecules of thrombin. Therefore, it is possible that by inhibiting upstream to thrombin, oral factor Xa inhibitors, such as apixaban, may be better than dabigatran for suppressing clotting on MHV.
mounting evidence that the root cause of thrombosis on blood-contacting medical devices is activation of factor XII. This explains why coating such devices with trypsin inhibitor, a potent and specific inhibitor of factor XIIa, or knocking down the levels of factor XII or factor XI with antisense oligonucleotides prevents such clotting. In the absence of oral inhibitors of factor XII or XI, oral factor Xa inhibitors may be the next best choice. Although the preclinical results with apixaban and rivaroxaban are promising, clinical trials are needed to assess their use in patients with MHV. The key issue will be determining the critical threshold of factor Xa inhibition required to prevent clotting on MHV and identifying oral dosing regimens capable of achieving them. From being restricted to warfarin, we now have the knowledge and tools to devise better and more convenient anticoagulant regimens for patients with MHV, but considerably more work remains to be done.

Disclosures
None.

References


Key Words: Editorial ■ anticoagulants ■ atrial fibrillation ■ factor Xa ■ heart valves ■ stroke
Anticoagulation for Mechanical Heart Valves: Will Oral Factor Xa Inhibitors Be Effective?
Noel C. Chan, Jeffrey I. Weitz and John W. Eikelboom

doi: 10.1161/ATVBAHA.117.309223
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2017 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/37/5/743

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at: http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at: http://atvb.ahajournals.org//subscriptions/